摘要:
Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant Aβ peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L′ is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.
摘要:
Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant Aβ peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L′ is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.
摘要:
The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)-(C)-(D) (I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.
摘要:
The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)—(C)-(D) (I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.
摘要:
There are provided, inner alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.
摘要:
Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a GABAB antagonist, or a blocker of Kir3.2 potassium channels, is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications.
摘要:
A method of treating an individual having Down syndrome or Alzheimer's disease, which entails the step of administering an amount of one or more compounds to the individual which improve cognitive functioning in the individual by increasing hippocampal NE levels.
摘要:
The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. A multilumen flow path allows exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.